GSK Shutters Plant on Bacteria Concerns

GlaxoSmithKline has temporarily shuttered a plant in the US state of North Carolina that produces inhaled medications after routine testing found the bacteria that causes Legionnaire's disease in a self-standing cooling tower.

A spokesperson for the plant near the state capital of Raleigh said testing is conducted every three months, but the company was seeking "more details on whether product has been impacted” and determining the procedure for handling it.

The facility produces inhaled drugs such as the asthma treatment Advair, and also toll manufactures for other pharmaceutical companies. Local officials said they were not aware of any Legionnaire's disease cases associated with the Glaxo plant.

According to reports, the same bacteria was found in cooling tanks in the Bronx borough of New York City earlier this summer, which is believed to have caused 12 deaths from Legionnaires' disease.

The US Centers for Disease Control and Prevention, based in Atlanta, Georgia, said about 8,000 to 18,000 Americans are hospitalized with the illness annually.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read